Eevia Health Receives a Sales Order for 638 KSEK (KUSD 59)

Eevia Health ("Eevia" or "The Company") received a KSEK 638 / KUSD 59 sales order draw for the elderberry extract Feno-Sambucus™ 7 ORGANIC from a US customer.

The end customer is a young brand owner within organic supplements and health products. The sales order is from Select Ingredients, a company working out of San Diego, California, US. Select Ingredients specializes in organic ingredients and high-quality natural plant extracts and serves branded customers in the Golden State and other large US states.

The order is for Feno-Sambucus™ 7 ORGANIC, an organically certified elderberry extract with a standardized level of anthocyanins that complies with key monographs, such as the United States Pharmacopeia. However, due to Eevia's production and purification approach, the product contains more other polyphenols than comparable extracts. It is documented in pre-clinical vivo testing in 138 biomarkers that Eevia's extract has a better bioactivity performance than similar competing products.

The sales value in euros is KEUR 56 (KSEK 638) FCA Finland and the order is a repeat order from the end customers.

 

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: [email protected]                      

Telephone: +358 400 22 5967                         

 

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing biomaterials that may dramatically impact human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.


Om Eevia Health

Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.

Webbplats
eeviahealth.com/investors

Handelsinformation

Kurs ()
Förändring ()
Marknad Spotlight stock market Kortnamn EEVIA ISIN-kod FI4000496658

IR-Kontakt

Stein Ulve IR-kontakt [email protected]